author-photo

Elna van der Ryst

Pfizer

26

Papers

2569

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.

2021 The Lancet HIV
Show All
- Source
- Cite
- Save
Citations (8)
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials

2019 Antiviral Chemistry & Chemotherapy
Show All
- Source
- Cite
- Save
Citations (0)
First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.

2019 New Microbiologica
Show All
- Source
- Cite
- Save
Citations (0)
Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

2017 Pediatric Infectious Disease Journal
Show All
- Source
- Cite
- Save
Citations (8)
The maraviroc expanded access program - safety and efficacy data from an open-label study.

2015 Hiv Clinical Trials
Show All
- Source
- Cite
- Save
Citations (9)
Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay

2015 Annals of the New York Academy of Sciences
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and safety of Maraviroc vs. Efavirenz in treatment-naive patients with HIV-1: 5-year findings

2014 AIDS
Show All
- Source
- Cite
- Save
Citations (33)
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.

2011 Antiviral Therapy
Show All
- Source
- Cite
- Save
Citations (22)
Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trials

2010 Hiv Clinical Trials
Show All
- Source
- Cite
- Save
Citations (2)
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection

2010 The Journal of Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (247)